Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The shares listed in Rows 5 and 7 consist of (i) (a) 1,190,999 shares of common stock, $0.0001 par value per share (the Common Stock) of Eikon Therapeutics, Inc. (the Issuer) and (b) options to purchase 1,417,315 shares of Common Stock, exercisable within 60 days of March 31, 2026, held directly by Dr. Roger M. Perlmutter, and (ii) 284,857 shares of Common Stock held directly by Perlmutter Consulting, Inc. Dr. Perlmutter is the president and sole shareholder of Perlmutter Consulting, Inc. and may be deemed to have sole power to vote and to dispose its shares. The percentage in Row 11 is based on 54,138,555 shares of Common Stock outstanding on March 17, 2026 as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026.


SCHEDULE 13G



 
PERLMUTTER ROGER M
 
Signature:/s/ Roger M. Perlmutter
Name/Title:Roger M. Perlmutter
Date:05/13/2026